New study compares drug to natural course of rare liver disease
NCT ID NCT07497724
First seen Apr 08, 2026 · Last updated May 12, 2026 · Updated 5 times
Summary
This study looks at a rare inherited liver disease called PFIC, which causes severe itching and liver damage. Researchers compared patients who took the drug odevixibat to similar patients who did not receive the drug, using data from a patient registry. The goal was to see if odevixibat helps avoid liver transplants, surgery, or death over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PFIC - PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Not applicable - retrospective secondary use of data
Paris, France
Conditions
Explore the condition pages connected to this study.